Table 2.

Risk factors of ischemic events — criteria for extended treatment with a second antithrombotic agent according to the 2020 ESC NSTE-ACS guidelines [11].

High thrombotic risk	Moderate thrombotic risk
Complex CAD and at least 1 criterion	Non-complex CAD and at least 1 criterion
Risk enhancers: DM requiring medication Recurrent MI Multivessel CAD Polyvascular disease (CAD plus PAD) Premature (< 45 years) or accelerated (new lesion within a 2-year time frame) CAD Concomitant systemic inflammatory disease (e.g. human immunodeficiency virus, systemic lupus erythematosus, chronic arthritis) CKD with eGFR 15–59 mL/min/1.73 m2 Technical aspects: ≥ 3 stents implanted ≥ 3 lesions treated Total stent length > 60 mm Previous complex revascularization (left main, bifurcation stenting with ≥ 2 stents implanted, chronic total occlusion, stenting of last patent vessel) Previous stent thrombosis on antiplatelet treatment	DM requiring medication Recurrent MI Polyvascular disease (CAD plus PAD) CKD with eGFR 15–59 mL/min/1.73 m2

CAD — coronary artery disease; CKD — chronic kidney disease; DM — diabetes mellitus; eGFR — estimated glomerular filtration rate; MI — myocardial infarction; PAD — peripheral artery disease